Hisham Elhaddad
Managing Partner at HOF Capital
New York, New York
Overview
Work Experience
Co-Founder / Managing Partner
2015 - Current
HOF Capital is a multi-stage venture capital firm with $1.4B in AUM. Backed by over 200 strategic institutions, we look for relentlessly ambitious founders and help them build generational companies.
HOF Capital is a global multistage VC firm with $1 billion in AUM that partners with ambitious entrepreneurs from idea to IPO.
Investor
2024
XAI is an AI company that develops a platform to accelerate human scientific discovery.
Raised $12,384,679,312.00 from Valor Equity Partners, Sequoia Capital, Andreessen Horowitz, Qatar Investment Authority and CoreNest Capital.
Investor
2023
Anthropic is an AI safety and research company that focuses on increasing the safety of large-scale AI systems.
Raised $13,740,377,627.00 from Amazon.
Investor
2021
Investor
2020
Insitro is a drug discovery and development startup that utilizes machine learning and biology to transform drug discovery.
Raised $643,000,000.00 from Alexandria Venture Investments, BlackRock, HOF Capital, CPP Investments, Google Ventures, Foresite Capital, Casdin Capital, Temasek Holdings, T. Rowe Price and Third Rock Ventures.
Investor, Board Member
2020
Blank Street is a coffee chain that offers coffee as a daily ritual that more people can enjoy, in places convenient to their lives.
Raised $113,824,340.00 from General Catalyst, HOF Capital, Left Lane Capital and Tiger Global Management.
Investor
2020
Investor
2019
Metagenomi uses metagenomics and machine learning to discover novel genome editing systems for therapeutics development.
Raised $456,973,182.00 from Novo Holdings, SymBiosis LLC, Catalio Capital Management, Leaps by Bayer, Moderna, Leaps by Bayer, Frazier Healthcare Partners, Bristol-Myers Squibb and Millennium Management.
Investor
2019
UiPath is a software company that designs and develops robotic process automation and artificial intelligence applications.
Raised $1,993,025,000.00 from Turkgen Ventures.
Investor
2019
BillionToOne is a precision diagnostics company that focuses on genetic testing for disease detection.
Raised $425,900,000.00 from Baillie Gifford, Civilization Ventures, Neuberger Berman, Adams Street Partners, Libertus Capital, PremjiInvest, Hummingbird Ventures and Fifty Years.